Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

In support of improving patient care, the Consortium of Multiple Sclerosis Centers (CMSC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This knowledge-based activity (UAN #JA4008165-9999-21-009-H01-P) qualifies for 1.25 contact hours (.125 CEUs) of continuing pharmacy education credit.

Acknowledgment of Support

This activity is supported by an educational grant from Genentech, Inc.

Clinical Consultations™: SARS-CoV-2 Vaccination in Patients with MS – What Clinicians Need to Know Now

Release Date: June 29, 2021
Expiration Date: June 29, 2022

Activity Overview

This Clinical Consultations™ is a video-based program in which two experts discuss the management of patients with multiple sclerosis (MS) and SARS-CoV-2 vaccinations. In this activity, the faculty focus on the effects of disease modifying therapies (DMTs) on vaccine practices, specifically the mRNA vaccines for SARS-CoV-2. This engaging format is designed to help clinicians identify best practices in the management of patients with MS and to improve outcomes for their patients with this disease in the era of COVID-19.

There are over a dozen FDA-approved DMTs to treat patients with MS. These therapies have various effects on humoral and cellular immunity, which are the key components in the protective immune response generated by vaccinations. In the midst of the COVID-19 pandemic, several mRNA-based vaccines for SARS-CoV-2 have been developed. Their effectiveness is based in part on the cell-mediated adaptive immune response. It is this cell-mediated response to vaccines that is of particular importance to clinicians who manage patients with MS, as patients who are treated with DMTs face challenges with respect to the interaction between DMTs that affect the humoral immune response and vaccines in general.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This activity is intended for community neurologists, MS specialists, specialty NPs, PAs, RNs, pharmacists and other members of the MS care team.

*Pharmacists

Upon successful completion of the activity, individual CE credits will be submitted electronically to the NABP CPE Monitor service. Paper certificates are not valid. For information about the CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the effects of vaccines on the immune response
  • Outline the mechanisms of action of vaccines targeting SARS-CoV-2
  • Describe the impact of disease modifying therapies used in the management of MS on response to vaccines
  • Incorporate evidence-based SARS-CoV-2 vaccination strategies into disease management plans for patients with MS

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Amit Bar-Or MD FRCPC
Amit Bar-Or MD FRCPC
Melissa and Paul Anderson Chair
Professor of Neurology
Director, Center for Neuroinflammation and Experimental Therapeutics
Chief, Division of MS and Related Disorders
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Research Support: Accure Therapeutics, Atara Biotherapeutics, Biogen, Bristol Myers Squibb/Celgene/Receptos, GlaxoSmithKline, Gossamer Bio, Janssen/Actelion, MedImmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi Genzyme. Consultant: Accure Therapeutics, Atara Biotherapeutics, Biogen, Bristol Myers Squibb/Celgene/Receptos, GlaxoSmithKline, Gossamer Bio, Janssen/Actelion, MedImmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi Genzyme.

Fred D. Lublin, MD
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine
Mount Sinai
New York, New York

Disclosures: Grant/Research Support: Novartis, Janssen/Actelion, Biogen, Sanofi, National Multiple Sclerosis Society, NIH, BrainStorm Cell Therapeutics. Consultant: Biogen, Merck/EMD Serono, Novartis, Teva, Janssen/Actelion, Sanofi Genzyme, Acorda Therapeutics, Roche/Genentech, MedImmune/Viela Bio, Bristol Myers Squibb/Celgene/Receptos, TG Therapeutics, Medday Pharmaceuticals, Atara Biotherapeutics, Mapi Pharma, Apitope, Orion Biotechnology, BrainStorm Cell Therapeutics, Jazz Pharmaceuticals, GW Pharmaceuticals, Mylan, Immunic, Population Council, Avotres, Neurogene, Banner Life Sciences. Speaker's Bureau: Sanofi (non-promotional), Merck/EMD Serono (non-promotional). Stock/ Shareholder: Avotres.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By